Mixed results for Boston Scientific:
This article was originally published in Clinica
Executive Summary
First-quarter sales for Boston Scientific rose by 9% to $470 million, although net income dropped to $67 million, compared with $75 million in the previous period. Excluding currency effects, sales rose by 13%. Peter Nicholas, chairman and CEO, said that the results were in line with expectations. The company conceded that it was disadvantaged by the fact that it had not yet obtained marketing approval for its NIR and Radius stents in the US and Japan, but said they were making progress.
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.